| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1179/JOC.1995.7.4.311 |
| P698 | PubMed publication ID | 8568543 |
| P2093 | author name string | Periti P | |
| P2860 | cites work | Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection | Q28328534 |
| Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity? | Q28329301 | ||
| Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides | Q28361967 | ||
| Vancomycin enhancement of experimental tobramycin nephrotoxicity | Q28362084 | ||
| What preclinical data are needed to justify once-daily therapy? | Q30899947 | ||
| Fever and associated changes in glomerular filtration rate erase anticipated diurnal variations in aminoglycoside pharmacokinetics | Q33751758 | ||
| Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982 | Q34055509 | ||
| Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring | Q34061646 | ||
| Evoked mechanical responses of isolated cochlear outer hair cells | Q34197131 | ||
| Determinants of efficacy and toxicity of aminoglycosides | Q34510814 | ||
| Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Tre | Q34722117 | ||
| Comparison of two methods for determining in vitro postantibiotic effects of three antibiotics on Escherichia coli | Q35298021 | ||
| Once-daily aminoglycoside dosing assessed by MIC reversion time with Pseudomonas aeruginosa | Q35820928 | ||
| Antibiotic uptake: unusual results for unusual molecules | Q36145865 | ||
| Single daily dose therapy with aminoglycosides | Q36517464 | ||
| Pneumonia caused by coliforms and Pseudomonas aeruginosa | Q36600483 | ||
| Impact of dosage schedule on the efficacy of gentamicin, tobramycin, or amikacin in an experimental model of Serratia marcescens endocarditis: in vitro-in vivo correlation | Q36752610 | ||
| First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. | Q36752618 | ||
| Bactericidal effect of gentamicin peak concentration provides a rationale for administration of bolus doses. | Q54653908 | ||
| Aminoglycoside-induced ototoxicity | Q57810563 | ||
| Single daily dosing of antibiotics: importance of in vitro killing rate, serum half-life, and protein binding | Q36755849 | ||
| Once-daily aminoglycoside therapy | Q37730823 | ||
| Once-daily aminoglycoside administration: new strategies for an old drug | Q38239743 | ||
| Once versus thrice daily gentamicin in patients with serious infections | Q39369365 | ||
| Pulse dosing versus continuous infusion of antibiotics. Pharmacokinetic-pharmacodynamic considerations | Q39637020 | ||
| Role of pharmacokinetics in the outcome of infections | Q39639407 | ||
| Clinical pharmacology of antibiotics and other drugs in cystic fibrosis | Q39654236 | ||
| Experience with a once-daily aminoglycoside program administered to 2,184 adult patients | Q39779327 | ||
| Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance | Q39828366 | ||
| Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model | Q39833928 | ||
| Pharmacokinetic and pharmacodynamic approach for comparing two therapeutic regimens using amikacin | Q39866827 | ||
| Adaptive resistance following single doses of gentamicin in a dynamic in vitro model. | Q39881843 | ||
| Serum level monitoring of antibacterial drugs. A review | Q40196347 | ||
| Simplified monitoring of aminoglycosides | Q40500490 | ||
| Pharmacokinetic contributions to postantibiotic effects. Focus on aminoglycosides | Q40589859 | ||
| Practicalities of once-daily aminoglycoside dosing | Q40664993 | ||
| Once-daily versus thrice-daily dosing of netilmicin in combination with beta-lactam antibiotics as empirical therapy for febrile neutropenic patients | Q40718971 | ||
| Aminoglycoside dosage regimens. Is once a day enough? | Q40720366 | ||
| Ceftriaxone plus conventional or single-daily dose amikacin versus ceftazidime/amikacin as empiric therapy in febrile neutropenic patients | Q40720512 | ||
| A study of amikacin given once versus twice daily in serious infections | Q41274203 | ||
| The analysis of dose-response curves--a practical approach | Q42003551 | ||
| Safety, pharmacokinetics and efficacy of once-a-day netilmicin and amikacin versus their conventional schedules in patients suffering from pelvic inflammatory disease | Q42150030 | ||
| Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models | Q42169493 | ||
| Incidence of amikacin ototoxicity: a sigmoid function of total drug exposure independent of plasma levels | Q42198825 | ||
| The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess | Q42208982 | ||
| Renal and auditory toxicity of high-dose, prolonged therapy with gentamicin and tobramycin in pseudomonas endocarditis | Q42248893 | ||
| Influence of dosage regimen on experimental tobramycin nephrotoxicity. A biochemical approach | Q42254296 | ||
| Once-daily gentamicin versus once-daily netilmicin in patients with serious infections--a randomized clinical trial. | Q42283857 | ||
| Failure of a nomogram to achieve target aminoglycoside concentrations | Q42908644 | ||
| Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone | Q43459102 | ||
| Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model | Q43617611 | ||
| Clinical use and toxicity of high-dose tobramycin in patients with pseudomonal endocarditis. | Q43632981 | ||
| Comparison of gentamicin dosing regimens using an in-vitro model. | Q43779314 | ||
| Distribution of gentamicin by immunofluorescence in the guinea pig inner ear. | Q44068655 | ||
| The effect of dosing strategy on kidney cortical accumulation of aminoglycosides in rats | Q44092671 | ||
| Pharmacologic factors associated with gentamicin nephrotoxicity in rabbits | Q44382589 | ||
| Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration | Q44483617 | ||
| Antimicrobial Activity of Subinhibitory Concentrations of Ciprofloxacin against <i>Pseudomonas aeruginosa </i>as Determined by the Killing Curve Method and the Postantibiotic Effect | Q44757345 | ||
| Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against gram-negative bacilli | Q44772163 | ||
| The Influence of Dosage Regimen on Experimental Gentamicin Nephrotoxicity: Dissociation of Peak Serum Levels from Renal Failure | Q45199122 | ||
| Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia | Q46611376 | ||
| Amikacin once daily: a new dosing regimen based on drug pharmacokinetics. | Q52424747 | ||
| The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. | Q52695343 | ||
| What is the evidence for once-daily aminoglycoside therapy? | Q52881617 | ||
| Aminoglycoside dosing: time to change. | Q54198578 | ||
| Post-antibiotic effect of ceftazidime, ciprofloxacin, imipenem, piperacillin and tobramycin for Pseudomonas cepacia | Q54259678 | ||
| Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. | Q54319060 | ||
| Adaptive resistance to aminoglycoside antibiotics in Pseudomonas aeruginosa. | Q54355199 | ||
| The aminoglycosides: streptomycin, kanamycin, gentamicin, tobramycin, amikacin, netilmicin, and sisomicin. | Q54399156 | ||
| Bactericidal effect of gentamicin trough concentration provides a rationale for administration of bolus doses and maintenance of trough levels. | Q54634009 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 311-337 | |
| P577 | publication date | 1995-08-01 | |
| P1433 | published in | Journal of Chemotherapy | Q15754073 |
| P1476 | title | Preclinical and clinical evaluation of once-daily aminoglycoside chemotherapy | |
| P478 | volume | 7 |
| Q45137694 | Antibiotic-induced release of bacterial cell wall components in the pathogenesis of sepsis and septic shock: a review |
| Q33541485 | Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen |
| Q46094288 | Enzymuria determination in children treated with aminoglycosides drugs. |
| Q33694699 | New criteria for selecting the proper antimicrobial chemotherapy for severe sepsis and septic shock |
| Q40949900 | Pharmacoeconomic evaluation of once-daily aminoglycoside treatment |
Search more.